BeOne Medicines (NASDAQ:ONC) Given New $405.00 Price Target at Barclays

BeOne Medicines (NASDAQ:ONC) had its price objective upped by Barclays from $394.00 to $405.00 in a report published on Friday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other equities analysts have also recently issued reports on ONC. Sanford C. Bernstein upgraded BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 target price on the stock in a report on Monday, January 12th. Citigroup increased their price target on shares of BeOne Medicines from $399.00 to $405.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a report on Wednesday, January 21st. Morgan Stanley reissued an “overweight” rating and issued a $405.00 price target on shares of BeOne Medicines in a report on Thursday, January 8th. Finally, Royal Bank Of Canada raised their price objective on BeOne Medicines from $417.00 to $425.00 and gave the stock an “outperform” rating in a research note on Thursday. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, BeOne Medicines presently has a consensus rating of “Moderate Buy” and a consensus target price of $394.25.

BeOne Medicines Trading Down 1.7%

ONC stock traded down $5.38 during midday trading on Friday, reaching $316.99. The company’s stock had a trading volume of 364,170 shares, compared to its average volume of 252,166. The business’s 50-day simple moving average is $336.81 and its 200-day simple moving average is $330.41. The company has a quick ratio of 2.17, a current ratio of 2.39 and a debt-to-equity ratio of 0.03. BeOne Medicines has a 52 week low of $196.45 and a 52 week high of $385.22. The stock has a market cap of $34.76 billion, a PE ratio of 125.79 and a beta of 0.52.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($1.02). BeOne Medicines had a net margin of 5.37% and a return on equity of 11.10%. The company had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. As a group, sell-side analysts expect that BeOne Medicines will post -5.82 EPS for the current year.

Insiders Place Their Bets

In other BeOne Medicines news, CEO John Oyler sold 24,369 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $302.87, for a total transaction of $7,380,639.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Chan Henry Lee sold 1,660 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $349.52, for a total value of $580,203.20. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 102,656 shares of company stock worth $31,567,496. 6.62% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ONC. Capital International Investors lifted its stake in BeOne Medicines by 1.3% in the 4th quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock valued at $1,553,909,000 after acquiring an additional 67,808 shares in the last quarter. Primecap Management Co. CA bought a new stake in shares of BeOne Medicines in the second quarter worth $1,231,720,000. Temasek Holdings Private Ltd bought a new stake in shares of BeOne Medicines in the second quarter worth $244,603,000. Siren L.L.C. boosted its holdings in shares of BeOne Medicines by 1.4% in the 4th quarter. Siren L.L.C. now owns 500,000 shares of the company’s stock valued at $151,905,000 after buying an additional 7,010 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in shares of BeOne Medicines in the second quarter valued at $113,190,000. 48.55% of the stock is currently owned by institutional investors.

Key Stories Impacting BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Analysts raised price targets — Truist boosted its target to $412 (buy), implying ~30% upside from the cited reference price. Benzinga
• Positive Sentiment: Guggenheim raised its target to $410 (buy), signaling similar upside (~29%). Benzinga
• Positive Sentiment: Barclays raised its target to $405 and kept an overweight rating, another vote of confidence from sell‑side analysts. Benzinga
• Neutral Sentiment: Revenue beat — Q4 revenue was $1.50B vs. consensus ~$1.45B, showing top‑line strength even as other metrics disappointed. Earnings Presentation
• Neutral Sentiment: Analyst/coverage writeups and Q4 metric breakdowns are available (Zacks, Seeking Alpha, Yahoo) for investors wanting full detail on margins, ROE and segment performance. Zacks Analysis Yahoo
• Neutral Sentiment: Reported short‑interest data in the feed shows zero/NaN values and a 0.0 days‑to‑cover ratio — likely data reporting issues rather than a meaningful change in short activity.
• Negative Sentiment: Large EPS miss — Q4 EPS of $0.58 missed consensus ~$1.60 by ~$1.02, a key negative that pressured sentiment despite revenue strength. (See Q4 results commentary.)
• Negative Sentiment: Disappointing FY2026 guidance — company issued revenue guidance of ~$6.2–6.4B vs. consensus ~6.5B, which the market viewed as conservative and has weighed on the stock. Investing.com
• Negative Sentiment: Coverage/articles highlight the post‑earnings selloff and investor reassessment after the EPS miss and guidance gap. YicaiGlobal

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.